Umfang:
1 Online-Ressource (XXXIV, 652 S.)
,
Illustrationen
Ausgabe:
1. ed.
ISBN:
0123740282
,
9780123740281
,
9781281795427
,
9780080559582
Inhalt:
Cover -- PARKINSON'S DISEASE: MOLECULAR AND THERAPEUTIC INSIGHTS FROM MODEL SYSTEMS -- COPYRIGHT PAGE -- CONTENTS -- LIST OF CONTRIBUTORS -- PREFACE -- FOREWORD -- PART I: CLINICAL OVERVIEW -- Chapter 1: Clinical Aspects of Parkinson Disease -- Clinical Features of Parkinson Disease -- Diagnosis and Differential Diagnosis -- Treatment -- References -- Chapter 2: Genetics of Parkinson's Disease -- Genetics of Familial Parkinson's Disease -- Parkinsonism-plus Genes -- Sporadic PD, Genetic Associations and Familial Genes -- Perspectives -- Acknowledgements -- References -- Chapter 3: Neuropathology of Parkinson's Disease -- Introduction -- Gross and Microscopic Findings in PD -- Neuropathologic Staging of PD -- Molecular Biology of LBs and Neuronal Loss in PD -- LBs in Other Disorders -- Relevance of Neuropathology to PD Models -- References -- PART II: NON-HUMAN PRIMATE MODELS -- Chapter 4: Introduction to -- Conclusions -- Acknowledgements -- References -- Chapter 5: Systems Level Physiology of the Basal Ganglia, and Pathophysiology of Parkinson's Disease -- Introduction -- Circuit Anatomy of the Basal Ganglia -- Pathophysiology of Parkinsonism -- Conclusion -- References -- Chapter 6: Neuroprotection for Parkinson's Disease -- A Chronic (Stepwise) MPTP Primate Model -- Time Course of Nigrostriatal Degeneration after Chronic MPTP Treatment -- How Does that Fit with Human PD? -- Additional in vivo and ex vivo Markers -- A Clinically Relevant Design that Takes Advantage of the Model -- Disclosure -- References -- Chapter 7: The Use of Aged Monkeys to Study PD -- Age-Related Decline of Motor Activity in Primates: Relationship to PD -- Age-Related Downregulation of Dopaminergic Phenotype in Nigrostriatal System: Relationship to PD -- Age-Related Increase of -Synuclein: Relationship to PD -- Aged Monkeys as a Model of PD: Relationship to Function -- So why has not aging Processes Become a More Central Factor in PD Studies? -- Conclusions -- References -- Chapter 8: 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Mammalian Models of Parkinson's Disease -- Introduction -- MPTP Mouse Models of Parkinsonism -- Similarities and Differences Between Acute and Sub-Acute MPTP Mouse Models -- MPTP Monkey Models -- Biochemistry of Acute and Chronic Parkinsonism in Monkeys: Similarities and Differences -- Do Different Models Respond Differently to Anti-parkinsonian Therapies? -- Conclusions -- References -- Chapter 9: Non-Human Primate Models of Parkinson's Disease and Experimental Therapeutics -- Introduction -- Assessment of Motor Behavior in Non-human Primate Models of PD -- Non-Motor Features in MPTP-Lesioned Non-human Primates -- The MPTP-Lesioned Non-human Primate Model -- A Brief Retrospective of MPTP in Monkeys -- The Subtypes of the MPTP-Lesion Non-human Primate Model -- The Adverse Effects of MPTP-Lesioning -- Testing Pharmacological Therapies for Neuroprotective and Symptomatic Benefit -- Dyskinesia and Motor Complications in Non-human Primates -- Intrinsic Neuroplasticity and Behavioral Recovery -- Electrophysiological Studies of Basal Ganglia Function in the Non-human Primate Model of PD -- Other Neurotoxicants in Non-human Primates -- Conclusion -- Acknowledgements -- References -- PART III: RODENT TOXIN MODELS -- Chapter 10: Rod
Inhalt:
Parkinson's disease is the second most prevalent neurodegenerative disease and is characterized by the irreversible loss of dopamine neurons. Despite its high prevalence in society and many decades of research, the origin of the pathogenesis and the molecular determinants involved in the disorder has remained elusive. Confounding this issue is the lack of experimental models that completely recapitulate the disease state. The identification of a number of genes thought to play a role in the cell death, and development of both toxin and genetic models to explore the function of the genes both in unaffected and diseased cells are now providing new insights into the molecular basis of the neurodegeneration, as well as therapeutic approaches. In this reference, we will describe the advances and the advantages that various invertebrates, cell culture, rodents, and mammals provide in the identification of the molecular components and mechanisms involved in the cell death, and outline the opportunities that these systems provide in drug discovery. * Comprehensive and critical assessment of the utility of various model systems to identify the molecular components and pathways involved in Parkinson's disease * Describes the power of toxin and genetic models to identify novel therapeutic targets and compounds that can be used in PD * Current overviews of current status of PD research and discovery from bench-to-bedside * Provides novel insights and views on where the future of PD research may lead * Provides a powerful teaching tool and template to explore the utility of model systems to identify molecular pathways, molecular targets, and therapeutics that are applicable to a variety of neurological diseases
Anmerkung:
Includes bibliographical references and index. - Description based on print version record
,
Part I: Clinical overviewPart II: Non-human primate models -- Part III: Rodent toxin models -- Part IV: Rodent and other vertebrate genetic models -- Part V: Multicellular invertebrate models -- Part VI: Cell-based models -- Part VII: Cell-free models.
,
CoverPARKINSON'S DISEASE: MOLECULAR AND THERAPEUTIC INSIGHTS FROM MODEL SYSTEMS -- COPYRIGHT PAGE -- CONTENTS -- LIST OF CONTRIBUTORS -- PREFACE -- FOREWORD -- PART I: CLINICAL OVERVIEW -- Chapter 1: Clinical Aspects of Parkinson Disease -- Clinical Features of Parkinson Disease -- Diagnosis and Differential Diagnosis -- Treatment -- References -- Chapter 2: Genetics of Parkinson's Disease -- Genetics of Familial Parkinson's Disease -- Parkinsonism-plus Genes -- Sporadic PD, Genetic Associations and Familial Genes -- Perspectives -- Acknowledgements -- References -- Chapter 3: Neuropathology of Parkinson's Disease -- Introduction -- Gross and Microscopic Findings in PD -- Neuropathologic Staging of PD -- Molecular Biology of LBs and Neuronal Loss in PD -- LBs in Other Disorders -- Relevance of Neuropathology to PD Models -- References -- PART II: NON-HUMAN PRIMATE MODELS -- Chapter 4: Introduction to -- Conclusions -- Acknowledgements -- References -- Chapter 5: Systems Level Physiology of the Basal Ganglia, and Pathophysiology of Parkinson's Disease -- Introduction -- Circuit Anatomy of the Basal Ganglia -- Pathophysiology of Parkinsonism -- Conclusion -- References -- Chapter 6: Neuroprotection for Parkinson's Disease -- A Chronic (Stepwise) MPTP Primate Model -- Time Course of Nigrostriatal Degeneration after Chronic MPTP Treatment -- How Does that Fit with Human PD? -- Additional in vivo and ex vivo Markers -- A Clinically Relevant Design that Takes Advantage of the Model -- Disclosure -- References -- Chapter 7: The Use of Aged Monkeys to Study PD -- Age-Related Decline of Motor Activity in Primates: Relationship to PD -- Age-Related Downregulation of Dopaminergic Phenotype in Nigrostriatal System: Relationship to PD -- Age-Related Increase of -Synuclein: Relationship to PD -- Aged Monkeys as a Model of PD: Relationship to Function -- So why has not aging Processes Become a More Central Factor in PD Studies? -- Conclusions -- References -- Chapter 8: 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Mammalian Models of Parkinson's Disease -- Introduction -- MPTP Mouse Models of Parkinsonism -- Similarities and Differences Between Acute and Sub-Acute MPTP Mouse Models -- MPTP Monkey Models -- Biochemistry of Acute and Chronic Parkinsonism in Monkeys: Similarities and Differences -- Do Different Models Respond Differently to Anti-parkinsonian Therapies? -- Conclusions -- References -- Chapter 9: Non-Human Primate Models of Parkinson's Disease and Experimental Therapeutics -- Introduction -- Assessment of Motor Behavior in Non-human Primate Models of PD -- Non-Motor Features in MPTP-Lesioned Non-human Primates -- The MPTP-Lesioned Non-human Primate Model -- A Brief Retrospective of MPTP in Monkeys -- The Subtypes of the MPTP-Lesion Non-human Primate Model -- The Adverse Effects of MPTP-Lesioning -- Testing Pharmacological Therapies for Neuroprotective and Symptomatic Benefit -- Dyskinesia and Motor Complications in Non-human Primates -- Intrinsic Neuroplasticity and Behavioral Recovery -- Electrophysiological Studies of Basal Ganglia Function in the Non-human Primate Model of PD -- Other Neurotoxicants in Non-human Primates -- Conclusion -- Acknowledgements -- References -- PART III: RODENT TOXIN MODELS -- Chapter 10: Rod.
Weitere Ausg.:
ISBN 9780080559582
Weitere Ausg.:
ISBN 0080559581
Weitere Ausg.:
ISBN 9780123740281
Weitere Ausg.:
Print version Parkinson's Disease molecular and therapeutic insights from model systems
Weitere Ausg.:
Erscheint auch als Druck-Ausgabe Parkinson's disease Amsterdam : Elsevier; Academic Press, 2008 ISBN 0123740282
Weitere Ausg.:
ISBN 9780123740281
Sprache:
Englisch
Schlagwort(e):
Electronic books
;
Electronic books
Bookmarklink
